

Robert J Moots

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/966435/robert-j-moots-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

3,672
citations

31
h-index

60
g-index

108
ext. papers

4,729
ext. citations

4.9
avg, IF

5.6
L-index

#	Paper	IF	Citations
90	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet, The</i> , 2021 ,	4.0	7
89	Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. <i>Rheumatology</i> , 2021 , 60, 4158-4165	3.9	3
88	Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. <i>Rheumatology</i> , 2021 , 60, 3189-3198	3.9	3
87	Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?-observations from the UK JSLE Cohort Study. <i>Rheumatology</i> , 2021 , 60, 5271-5281	3.9	8
86	POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 593-594	2.4	
85	Internalization of Neutrophil-Derived Microvesicles Modulates TNF α -stimulated Proinflammatory Cytokine Production in Human Fibroblast-Like Synoviocytes. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
84	Anti-TNF biosimilars in rheumatology: the end of an era?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 29-36	5.4	2
83	Type I interferon regulates cytokine-delayed neutrophil apoptosis, reactive oxygen species production and chemokine expression. <i>Clinical and Experimental Immunology</i> , 2021 , 203, 151-159	6.2	3
82	Isolation of Microvesicles from Human Circulating Neutrophils. <i>Bio-protocol</i> , 2021 , 11, e3119	0.9	0
81	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 305-317	4.0	42
80	Behçet's syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study. <i>Rheumatology</i> , 2021 , 60, 4728-4736	3.9	2
79	Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. <i>Rheumatology</i> , 2021 , 60, 5734-5742	3.9	0
78	APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNF α expression and signalling. <i>Inflammopharmacology</i> , 2020 , 28, 1223-1235	5.1	3
77	OP0220 ASSESSING THE EFFECT OF INCREASED BODY MASS INDEX ON RESPONSE TO TNF INHIBITORS IN ESTABLISHED RHEUMATOID ARTHRITIS: RESULTS FROM THE METEOR DATABASE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 137.1-137	2.4	0
76	OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 187.1-188	2.4	1
75	An update on the general management approach to common vasculitides. <i>Clinical Medicine</i> , 2020 , 20, 572-579	1.9	3
74	Biomarkers for treatment response in rheumatoid arthritis: Where are they?. <i>Rheumatology and Immunology Research</i> , 2020 , 1, 1-3	0.2	2

73	Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, iv47-iv57	3.9	17
72	Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. <i>Arthritis Care and Research</i> , 2020 , 72, 591-599	4.7	11
71	Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps. <i>Frontiers in Immunology</i> , 2020 , 11, 584116	8.4	24
70	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e000885	5.9	9
69	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. <i>Rheumatology</i> , 2019 , 58, 2025-2030	3.9	14
68	012 Proteomic analysis of neutrophil extracellular traps in rheumatoid arthritis and systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58,	3.9	1
67	Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1287-1288	2.4	3
66	Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019 , 10, 423	8.4	65
65	Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , 2019 , 58, 1746-1754	3.9	23
64	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 752-762	5.3	38
63	The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1167-1178	2.4	80
62	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 177	5.7	4
61	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIb/IV trial. <i>RMD Open</i> , 2019 , 5, e001040	5.9	13
60	Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). <i>Rheumatology</i> , 2019 , 58, 811-819	3.9	16
59	Measuring disease activity and response to treatment in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 135-145	5.1	2
58	A novel treatment in the management of genital ulceration in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 121, 158	2.2	
57	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 808-818	2.4	277
56	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 412-416	2.4	53

55	Etanercept for the treatment of rheumatoid arthritis. <i>Immunotherapy</i> , 2018 , 10, 433-445	3.8	36
54	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 57	4.9	28
53	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018 , 57, 2200-2212	3.9	57
52	Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 84	4.9	17
51	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. <i>BioDrugs</i> , 2018 , 32, 193-199	7.9	20
50	Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. <i>Scandinavian Journal of Pain</i> , 2018 , 18, 29-37	1.9	6
49	Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients. <i>Drugs and Aging</i> , 2017 , 34, 255-264	4.7	16
48	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1440-1450	9.5	122
47	Behçet's disease. <i>Clinical Medicine</i> , 2017 , 17, 71-77	1.9	50
46	Fibromyalgia in Behçet's disease: a narrative review. <i>British Journal of Pain</i> , 2017 , 11, 97-101	2.1	4
45	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 457-468	4.0	227
44	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017 , 19, 37	4.9	62
43	Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 785-795	6.5	23
42	Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. <i>Rheumatology International</i> , 2017 , 37, 239-244	3.6	10
41	Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 599-611	6.5	68
40	THE CHALLENGES OF RARE RHEUMATIC DISEASES ¹⁹ . CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES. <i>Rheumatology</i> , 2017 , 56,	3.9	7
39	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017 , 12, e0175207	3.7	63
38	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017 , 56, 541-549	3.9	28

37	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52	3.9	7
36	Development of a Rheumatology-specific Patient Concerns Inventory and Its Use in the Rheumatology Outpatient Clinic Setting. <i>Journal of Rheumatology</i> , 2016 , 43, 779-87	4.1	6
35	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016 , 2, e000282	5.9	46
34	Inflammatory arthritis in HIV positive patients: A practical guide. <i>BMC Infectious Diseases</i> , 2016 , 16, 100	4	41
33	Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 679-84	2.2	
32	Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. <i>Rheumatology</i> , 2015 , 54, 188-93	3.9	73
31	Resveratrol and N-acetylcysteine influence redox balance in equine articular chondrocytes under acidic and very low oxygen conditions. <i>Free Radical Biology and Medicine</i> , 2015 , 86, 57-64	7.8	9
30	Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab. <i>Rheumatology</i> , 2015 , 54, 743-4	3.9	4
29	Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 77	2.8	24
28	Cutaneous immunopathology of long-standing complex regional pain syndrome. <i>European Journal of Pain</i> , 2015 , 19, 1516-26	3.7	14
27	Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 979-84	2.4	99
26	Whose Gene Is It Anyway? The Effect of Preparation Purity on Neutrophil Transcriptome Studies. <i>PLoS ONE</i> , 2015 , 10, e0138982	3.7	28
25	Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 737-45	2.2	12
24	Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. <i>Rheumatology</i> , 2014 , 53, 1595-603	3.9	38
23	Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. <i>Rheumatology</i> , 2014 , 53, 1321-31	3.3	110
22	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8	2.4	63
21	Expanded population of CD1d-restricted V α 4+ cells in a patient with active rheumatoid arthritis. <i>Clinical Immunology</i> , 2014 , 150, 140-2	9	1
20	The multifactorial role of neutrophils in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 593-601	8.1	311

19	FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A402.1-A402	2.4	
18	FRI0100 Treat to target: defining the optimum target to prevent radiographic erosion progression during the first year of treatment in an early rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A403.3-A404	2.4	1
17	SAT0049 Obesity is Associated with Reduced Improvement in Functional Disability After 1 Year of Treatment: Results from an Inception Early Rheumatoid Arthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A596.2-A596	2.4	1
16	RNA-seq reveals activation of both common and cytokine-specific pathways following neutrophil priming. <i>PLoS ONE</i> , 2013 , 8, e58598	3.7	72
15	Mavrimumab, a human monoclonal GM-CSF receptor-antibody for the management of rheumatoid arthritis: a novel approach to therapy. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1661-8	5.4	15
14	The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. <i>Rheumatology</i> , 2012 , 51, 2252-61	3.9	43
13	Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. <i>Rheumatology</i> , 2012 , 51, 451-9	3.9	76
12	Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries. <i>Rheumatology</i> , 2012 , 51, 393-6	3.9	6
11	Changes in expression of membrane TNF, NF- κ B activation and neutrophil apoptosis during active and resolved inflammation. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 537-43	2.4	60
10	Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2011 , 50, 1672-83	3.9	39
9	Neutrophil function in inflammation and inflammatory diseases. <i>Rheumatology</i> , 2010 , 49, 1618-31	3.9	515
8	Manifestations of systemic sclerosis necessitate a holistic approach to patient care: a case report. <i>Musculoskeletal Care</i> , 2010 , 8, 164-7	1.6	
7	Behcet's syndrome. <i>BMJ, The</i> , 2009 , 339, b3876	5.9	2
6	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1687-99	5.9	6
5	The dual effects of TNF α on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. <i>Blood</i> , 2008 , 111, 878-84	2.2	72
4	Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. <i>Journal of Biological Chemistry</i> , 2004 , 279, 26915-21	5.4	187
3	Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2796-806		76
2	A fistful of T cells. <i>Rheumatology</i> , 1998 , 37, 602-11	3.9	6

- 1 Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective